NeuroField is an American neurotechnology company headquartered in Santa Barbara, California.[1] The company develops hardware and software for quantitative electroencephalography (QEEG) analysis and neuromodulation, including photobiomodulation and transcranial electrical stimulation devices.[2][3]
Company type | Private |
|---|---|
| Industry | Neurotechnology Medical devices |
| Founded | 2008 |
| Founders | Nicholas Dogris Brad Wiitala |
| Headquarters | Santa Barbara, California, U.S. |
| Website | neurofield |
History
editNeuroField was co-founded in 2008 by psychologist Nicholas Dogris and engineer Brad Wiitala.[1] The company initially focused on developing low-intensity pEMF devices synchronized with EEG for neurotherapy applications.[4]
NeuroField later received FDA 510(k) clearance for its Q21 EEG electroencephalograph, Analysis Suite and for the Genesis Sleep cranial electrotherapy stimulator.[5][6]
Technology
editReferences
edit- 1 2 "Neurofield Inc – Company Profile and News". Bloomberg. Retrieved 2026-02-23.
- 1 2 "NeuroField, Inc. MARCS-CMS 621767 — February 28, 2022". U.S. Food and Drug Administration. 2022-02-28. Retrieved 2026-02-23.
- ↑ "NeuroField Neurotherapy Provides Services Designed to Optimize Brain Function". Noozhawk. Retrieved 2026-02-23.
- ↑ Dogris, Nicholas (2011). "Neurofield: Three Case Studies". Journal of Neurotherapy. 15 (1): 75–83. doi:10.1080/10874208.2010.545754. Retrieved 2026-02-23.
- 1 2 "510(k) Premarket Notification – NeuroField Analysis Suite". U.S. Food and Drug Administration. Retrieved 2026-02-23.
- 1 2 "510(k) Premarket Notification – Genesis Sleep". U.S. Food and Drug Administration. Retrieved 2026-02-23.